Avigen, Inc. Stops Development of Lead Drug; Reduces Headcount by 70%

Dec 22 (Reuters) - Biopharmaceutical company Avigen Inc said it would stop all clinical trials of its experimental treatment for spasticity related to multiple sclerosis, which failed a mid-stage trial in October.